
IgA Nephropathy
Latest News
Latest Videos

Podcasts
CME Content
More News

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

Andrew Vissing shares his clinical perspective and strategies to mitigate gaps in care and management for young adults with glomerular disease.

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN.

IgA nephropathy advanced in 2025 with FDA approvals, positive phase 3 trials, and growing disease-modifying therapies

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables.

A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy
FDA grants accelerated approval for sibeprenlimab for reducing proteinuria in IgA nephropathy.

Pediatric IgA nephropathy shows slow progression, high remission rates, and frequent relapse, with new risk factors identified to improve long-term prognosis and management.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.





















































